In particular, we report that IRF8 expression predicts the complete pathological response to monoclonal antibody therapy (trastuzumab) or to certain combinations of chemotherapy such as FAC (fluorouracil, adriamycin, and cytoxan) in these BC subtypes. The gene discussed is IRF8; the disease is breast cancer.